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DOI 10.1016/j.ccr.2011.12.021SUMMARYMedulloblastoma (MB) is the most commonmalignant brain tumor in children. Patients whose tumors exhibit
overexpression or amplification of theMYC oncogene (c-MYC) usually have an extremely poor prognosis, but
there are no animal models of this subtype of the disease. Here, we show that cerebellar stem cells express-
ing Myc and mutant Trp53 (p53) generate aggressive tumors following orthotopic transplantation. These
tumors consist of large, pleiomorphic cells and resemble human MYC-driven MB at a molecular level.
Notably, antagonists of PI3K/mTOR signaling, but not Hedgehog signaling, inhibit growth of tumor cells.
These findings suggest that cerebellar stem cells can give rise to MYC-driven MB and identify a novel model
that can be used to test therapies for this devastating disease.INTRODUCTION
Medulloblastoma (MB) is a highly malignant tumor of the cere-
bellum that occurs most frequently in children between 5 and
10 years of age (Polkinghorn and Tarbell, 2007). Current treat-
ment for MB includes resection of the tumor followed by radia-
tion and high-dose chemotherapy. Although this has resulted
in significant increases in survival, approximately one-third ofSignificance
Animal models are valuable for studying the origins and molec
test new therapeutic strategies. Existing mouse models of MB
Sonic hedgehog pathway mutations. In contrast, no models
describe a mouse model of this tumor based on transplantat
negative p53. These tumors resemble human MYC-driven MB
by antagonists of the PI3K/mTOR pathway. This model repre
peutic responsiveness of MYC-driven MB.
CMBpatients still die from their disease. Moreover, survivors often
suffer severe side effects, including dramatic losses in cognitive
function, endocrine disorders, and increased susceptibility to
secondary tumors (Palmer et al., 2007; Stavrou et al., 2001).
Thus, more effective and less toxic therapies for MB are desper-
ately needed.
Traditionally, MB has been classified based on histological
characteristics. In this context, tumors with large-cell-anaplasticular mechanisms of cancer and can be used to develop and
have been extremely useful for studying MB associated with
have been developed to study MYC-driven MB. Here we
ion of cerebellar stem cells expressing Myc and dominant-
at a histological and molecular level and can be inhibited
sents an important tool for studying the biology and thera-
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Figure 1. Myc Promotes Proliferation of Cerebellar Stem Cells
In Vitro
(A) Prom1+Lin cells sorted from cerebella of 5- to 7-day-old mice were in-
fected withMyc-IRES-GFP or control (GFP only) viruses for 48 hr, pulsed with
tritiated thymidine (3H-Td), and cultured overnight before being assayed for
3H-Td incorporation. Data represent the mean ± SEM of triplicate samples.
(B–D) Prom1+Lin cells infected with Myc-IRES-GFP or control viruses were
cultured at low density in the presence of EGF and bFGF for 7 days. Repre-
sentative fields are shown in (C) and (D) (scale bars = 100 mm). The number of
GFP+ neurospheres is quantified in (B); data represent the mean ± SEM of
triplicate samples. The infection efficiency was 80% withMyc-IRES-GFP and
90% with control retrovirus.
See also Figure S1.
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Modeling MYC-Driven Medulloblastoma(LCA) features are associated with amuch poorer prognosis than
classic or nodular/desmoplastic tumors (Eberhart and Burger,
2003; Leonard et al., 2001). Recently, several groups (Cho
et al., 2011; Kool et al., 2008; Northcott et al., 2011; Remke
et al., 2011; Thompson et al., 2006) have performed gene-
expression profiling and DNA-copy-number analysis of MB,
and have identified at least four major subtypes of the disease:
WNT, Sonic hedgehog (SHH), Group C, and Group D. These
molecular subtypes have distinct characteristics in terms of
gene expression, mutational profiles, epidemiology, and prog-
nosis. Among molecular subtypes, tumors associated with
WNT pathway activation have the most favorable outcome,
whereas those that exhibit overexpression or amplification of
MYC and lack WNT pathway activation (termed Group C (North-
cott et al., 2011) or Group c1 (Cho et al., 2011), herein referred to
as MYC-driven MB) have the worst prognosis. Although LCA
histology can be found in all molecular subtypes of the disease,
it is more common in MYC-driven tumors. Patients with MYC-
driven MB are also more likely to exhibit metastatic disease at
the time of diagnosis, to undergo recurrence, and to die of their
disease (Northcott et al., 2011). More effective treatments for
MYC-driven MB depend on a deeper understanding of the
biology of the disease.
The fact that ectopic expression of MYC can cause MB cell
lines to adopt an anaplastic phenotype (Stearns et al., 2006)156 Cancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc.and the fact that high MYC levels are associated with poor clin-
ical outcome (Cho et al., 2011; Grotzer et al., 2001) suggest that
MYC might play a key role in the biology of MB. But while the
association between MYC and poor prognosis is well estab-
lished, it remains unclear whether the gene is involved in tumor
initiation, maintenance, or progression. Likewise, MYC-driven
tumors frequently exhibit loss of one allele of the TP53 tumor
suppressor (in the context of isochromosome 17q) (Northcott
et al., 2011; Pfister et al., 2009), and LCA tumors have been
reported to express high levels of p53 protein, an indicator of
dysregulation of the TP53 pathway (Eberhart et al., 2005; Frank
et al., 2004). However, it is not clear whether alterations in
TP53 represent causal events.
Animal models of brain tumors can be generated by targeting
expression of oncogenes to neural progenitors or stem cells.
Recent studies suggest that different populations of progenitors
may be susceptible to transformation by distinct signaling
pathways (Gilbertson and Ellison, 2008). For example, mutations
in the SHH pathway promote transformation of granule neuron
precursors (GNPs) in the external germinal layer of the cere-
bellum (Schu¨ller et al., 2008; Yang et al., 2008), whereas dysre-
gulation of WNT signaling causes transformation of progenitors
in the lower rhombic lip and embryonic dorsal brainstem (Gibson
et al., 2010). We recently identified a population of stem cells in
the white matter of the postnatal cerebellum (Lee et al., 2005)
and hypothesized that they might give rise to some types of
MB. To test this hypothesis, and to address the functional
importance of MYC and TP53 in MB, we examined the effects
of overexpressing Myc and disrupting p53 function in these
cells.RESULTS
Myc Promotes Proliferation of Cerebellar Stem Cells
In Vitro
Stem cells can be isolated from the postnatal cerebellum based
on expression of Prominin1 (CD133) and lack of neuronal and
glial lineage markers (Prom1+Lin). To investigate the effects
of Myc on these cells, we infected them with control retrovi-
ruses or viruses encoding a stabilized form of Myc (MycT58A)
(Chang et al., 2000) and measured their proliferation. As shown
in Figure 1A, Myc-infected cells showed a 2.5-fold increase in
proliferation compared to cells infected with control viruses.
To examine the effects of Myc on self-renewal, infected
Prom1+ Lin cells were cultured at low density (2000 cells/ml)
in the presence of basic fibroblast growth factor (bFGF) and
epidermal growth factor (EGF) to promote neurosphere forma-
tion. As shown in Figures 1B–1D, the number of neurospheres
in Myc-infected cultures was 9-fold higher than that in control
cultures. To determine whether the effects of Myc persisted in
longer-term cultures, neurospheres were dissociated into
single-cell suspensions and replated every 7 days. Over the
course of 5 weeks, Myc-infected cultures exhibited a 1000-
fold increase in cell number, compared to a 2-fold increase in
control cultures (Figure S1 available online). These data indicate
that overexpression of Myc in cerebellar stem cells promotes
short-term proliferation, as well as long-term self-renewal
in vitro.
Figure 2. Myc-Infected Stem Cells Give Rise to Transient Hyper-
plastic Lesions following Transplantation
(A–F) Prom1+Lin cells were infected withMyc-IRES-GFP or control retrovirus
for 20 hr and then transplanted into the cerebella of NSG mice. Hosts were
sacrificed after 2.5 weeks. Frozen sections from mice that received GFP-in-
fected (A and B) or Myc-infected (C–F) cells were stained with anti-Ki67 anti-
bodies (A–D) or H&E (E and F). Note the large mass of proliferating (Ki67+) cells
seen in animals that received Myc-infected cells (C and D). The box in (E)
corresponds to the high-power field shown in (F). Scale bars = 50 mm (A–D and
F) and 100 mm (E).
(G and H) Prom1+ cells were infected with Myc-IRES-GFP or control-GFP
viruses for 20 hr and then transplanted into the cerebella of NSG hosts. Mice
were sacrificed after 2 weeks. Frozen sections frommice that received control
(G) or Myc-infected cells (H) were stained with antibodies specific for cleaved
caspase-3 (CC3) to detect apoptotic cells. Scale bars = 50 mm.
See also Figure S2.
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Hyperplastic Lesions In Vivo
In light of the above results, we investigated whether Myc-ex-
pressing cells could give rise to tumors in vivo. We stereotaxi-
cally implanted control (GFP virus-infected) or Myc-infected
stem cells into the cerebella of immunocompromised (NOD-
SCID-IL2RGammanull, or NSG) mice and examined cerebella of
recipients 2–3 weeks later. As shown in Figures 2A and 2B, in
animals that had received control cells, few infected cells
(marked by GFP) could be detected, and only a small proportionCof these were proliferating (based on Ki67 staining). In contrast,
in animals transplanted withMyc-expressing cells, large masses
of infected cells could be detected, and the majority of these
were proliferating (Figures 2C–2F). These results suggest that
Myc-infected cells can undergo persistent proliferation in vivo.
To determinewhetherMyc-infected cells can continue to grow
and give rise to tumors, we sacrificed animals (n = 5) four weeks
after transplantation. Surprisingly, at this stage, few transplanted
cells could be detected in the cerebella of mice that had received
either control orMyc-infected cells. Consistent with this, we fol-
lowed a cohort of mice (n = 6) transplanted with Myc-infected
cells for 6months, and found that none of themdeveloped symp-
toms during this period (data not shown). This suggested that
Myc can drive proliferation of stem cells, but is not sufficient to
promote tumor growth.
The fact thatMyc-infected cells formed large masses 2 weeks
after transplantation but were undetectable 4 weeks after trans-
plantation raised the question of what happened to these cells.
Since Myc can induce apoptosis as well as proliferation (Pelen-
garis et al., 2000), we examined cerebella from recipients of
control and Myc-infected cells for evidence of apoptosis by
staining with anti-cleaved caspase 3 (CC3). Few control virus-in-
fected cells were labeled with anti-CC3 (although some staining
was seen around the transplant site), whereasMyc-infected cells
exhibited a significant amount of CC3 staining (Figures 2G and
2H), suggesting that they were undergoing apoptosis in situ.
These data suggest that Myc promotes proliferation as well as
apoptosis of cerebellar stem cells.
Mutant p53 Synergizes with Myc to Promote Tumor
Formation
MYC-induced apoptosis is frequently dependent on TP53 (Her-
meking and Eick, 1994). To test whether inactivation of p53 could
inhibit Myc-induced cell death in cerebellar stem cells, we
measured apoptosis in cells infected with control (GFP), Myc,
dominant-negative p53 (DNp53) (Bowman et al., 1996), or
Myc + DNp53 viruses. As shown in Figures S2A–S2D, cells in-
fected with Myc viruses alone exhibited a marked increase in
apoptosis compared to cells infected with control viruses
(Figures S2A and S2B), but DNp53 completely abolished the
proapoptotic effects of Myc (Figures S2C and S2D). These
results suggest that Myc-mediated apoptosis of stem cells can
be blocked by inhibition of p53 function.
Theabovefindings raised thepossibility that cellsoverexpress-
ingMyc and DNp53might be able to give rise to tumors. To test
this, we coinfected stem cells with viruses encoding these genes
and implanted them into the cerebella of NSG mice. Animals
transplanted with cells coexpressing the two genes developed
highly aggressive tumors and had to be sacrificed at 6–12 weeks
(Figures 3A and 3B). These experiments were performed using
the T58A mutant of Myc. Notably, stem cells infected with WT
Myc +DNp53 also gave rise to tumors, albeit with reduced pene-
trance (33%) and longer latency (15–20 weeks). These studies
suggest that mutant p53 can cooperate with Myc to promote
transformation of cerebellar stem cells.
We characterized tumors arising from stem cells infected with
Myc and DNp53 (MP tumors), using tumors from Ptch1 mutant
mice (a model for SHH-associated MB) for comparison (Figures
3C–3H). Whereas Ptch1+/ tumor cells were not much biggerancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc. 157
Figure 3. Overexpression of Myc and Inactivation of p53 Transforms Cerebellar Stem Cells into Tumors
Prom1+Lin cells were infected withMyc + DNp53 retroviruses,Myc alone, or DNp53 alone for 20 hr, then transplanted into the cerebella of NSG mice. Animals
were sacrificed when they developed symptoms.
(A) Whole-mount image of tumor, with GFP expression originating from DNp53 retrovirus.
(B) Survival curve for animals receiving 5 3 104 cells infected withMyc viruses (blue line), DNp53 viruses (green line), orMyc + DNp53 viruses (red line) (median
survival 48 days).
(C–H) Sections of tumor tissue from animals transplanted with cells expressing Myc and DNp53 (C–E) or from Ptch1 mutant mice (F–H) were stained with
hematoxylin and eosin. For (C) and (F), scale bars = 100 mm; for (D), (E), (G), and (H), scale bars = 50 mm. Boxes in (C) and (F) refer to (D) and (G), respectively.
Asterisks in (C) and (D) show an area of necrosis and a large tumor cell with marked nuclear atypia (anaplasia), respectively. Horizontal arrows in (D) and (E) show
prominent nuclear molding. Arrowheads in (D), (G), and (H) showmitotic figures. Vertical arrows in (E) and (H) show normal granule neurons in the internal granule
layer (igl); the majority of tumor cells in (E) are much larger than these cells, whereas those in H are approximately the same size.
See also Figure S3.
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head in Figure 3H), cells from MP tumors were approximately 5
times bigger (25 mm, compare vertical and horizontal arrows
in Figure 3E). In addition, MP tumors exhibited prominent
necrosis (asterisk in Figure 3C) and nuclear molding (arrows in
Figures 3D and 3E), whereas Ptch1+/ tumors rarely displayed
these features (Figures 3G and 3H). Importantly, the histological
features of murine MP tumors resembled those of human LCA
(Group C) MB (Figure S3). Together these data suggested that
MP tumors are distinct from SHH-driven tumors and histologi-
cally resemble human LCA MB.
Immunohistochemical characterization of MP tumors demon-
strated that they have a high proliferative index and often
express the stem cell/progenitor marker Nestin (Figures 4A–
4C). Tumor cells that did exhibit differentiation predominantly
expressed the early neuronal lineage marker Tuj1 (class III
beta-tubulin; Figure 4D). Only rare tumor cells expressed the
mature neuronal marker synaptophysin (not shown) or the astro-
cytic marker GFAP (Figure 4E), consistent with the notion that
MP tumors are poorly differentiated. Tumors also did not
express O4, NG2, PDGFRa, or SOX10, markers associated
with oligodendrogliomas (data not shown). Finally, tumor cells
expressed significant amounts of the chromatin remodeling
protein BAF47 (also known as Smarcb1, Snf5, or Ini1), which is
commonly lost in atypical teratoid/rhabdoid tumor (AT/RT), sug-
gesting that we were not modeling this type of tumor (Figure 4F).
Based on these observations, we concluded that MP tumors are
highly proliferative and poorly differentiated, features consistent
with LCA MB.
MP Tumors Can Be Generated from Granule Neuron
Precursors
Previous studies have suggested that SHH-associated MB can
be initiated in GNPs or neural stem cells (Schu¨ller et al., 2008;158 Cancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc.Yang et al., 2008), We therefore determinedwhether GNPs could
also be transformed byMyc and DNp53. To test this, we FACS-
sorted GFP+ cells (GNPs) from neonatal Math1-GFP transgenic
mice (Lee et al., 2005; Lumpkin et al., 2003) (Figures S4A and
S4B), infected these cells with Myc and DNp53 viruses, and
then transplanted them into the cerebellum of NSG mice. We
found that 7 out of 22 recipients developed tumors, with a latency
of 108 days (Figures S4D–S4F). Interestingly, although the cells
were GFP+ prior to transplantation (Figure S4B), the tumors
that developed from them were no longer GFP+ when analyzed
by microscopy or flow cytometry (Figures S4C and S4E), sug-
gesting that they had lost a key marker of the granule lineage
during the course of transformation. These studies demonstrate
that both stem cells and GNPs can give rise to MYC-driven
tumors.
Myc Is Required to Maintain MP Tumor Growth
In many tumors driven by MYC, shutting off the expression of
MYC results in tumor regression (Jain et al., 2002; Soucek
et al., 2008). To determine whether MP tumors continue to
depend on Myc once they are established, we infected stem
cells with viruses encoding a tetracycline-inducible form of
Myc along with DNp53-IRES-Luciferase, and transplanted
these cells into the cerebellum of NSG mice. Mice were fed
doxycycline (DOX)-containing food until they developed tumors
(3–4 weeks after transplantation). Tumors were removed, disso-
ciated, and retransplanted into cerebella of naive NSG mice.
Secondary recipients were separated into three groups: Group
1 (n = 14) was maintained on DOX-containing food; Group 2
(n = 14) was fed DOX-containing food for 1 week, then switched
to normal food; and Group 3 (n = 12) was fed food without DOX
(Figure 5A). Animals in all groups developed bioluminescent
signals (from the luciferase encoded by the DNp53 virus), indi-
cating the presence of transplanted tumor cells. Group 1 animals
Figure 4. MP Tumors Exhibit Characteristics of Human MB
Cryosections fromMP tumors were stained with H&E (A) or with antibodies specific for Ki67 (B), Nestin (C), Tuj1 (D), GFAP (E), or BAF47/Ini1 (F). Images in (A)–(E)
represent adjacent sections. Scale bars = 50 mm.
See also Figure S4.
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ure 5B, top graph), and by 3-4 weeks after transplantation, all
mice had developed symptoms and had to be sacrificed (Fig-
ure 5F). Analysis of brains from these mice revealed large tumors
in every animal (Figure 5C). In contrast, bioluminescence in
Group 2 and Group 3 mice decayed in the absence of DOX (Fig-
ure 5B, bottom two graphs). Moreover, no tumors could be de-
tected in these animals 3 weeks after transplantation (Figures
5D and 5E), and animals remained asymptomatic at 6 weeks
(Figure 5F). Together these data suggest that Myc is not only
necessary for tumor initiation but is also required to maintain
growth of MP tumors.
MP Tumors Resemble Human MYC-Driven MB
Our histological analysis indicated that MP tumors resemble
human LCA MB. Since LCA histology is more common in
MYC-driven tumors (Cho et al., 2011; Northcott et al., 2011),
this supported the notion that MP tumors might represent
a model for human MYC-driven MB. To test whether MP tumors
resembled human MYC-driven MB at a molecular level, we per-
formed gene expression analysis of MP tumors and compared
the resulting gene expression profiles with profiles of the four
subtypes of human MB (WNT, SHH, Group C, and Group D)
defined by Northcott et al. (2011). In this classification scheme,
Group C tumors, which are associated with the poorest prog-
nosis, frequently exhibit amplification or overexpression of
MYC (Northcott et al., 2011). Using genes differentially ex-
pressed in each subgroup and previously published methods
(Bild et al., 2006), we identified four sets of genes (‘‘subgroup
signatures’’) whose expression accurately predicted the
subgroup of the humanMB samples (see Human Tumor Analysis
in the Supplemental Information).
Human MB subgroup signatures were then applied to gene
expression data from murine MP and Ptch1 mutant tumors,
with each tumor receiving a subgroup signature score represent-
ing its similarity to each subgroup of human MB. As shown in
Figure 6A and Table S1, murine Ptch1 tumors most closelyCresembled human SHH-associated tumors, with one exception,
which possessed a profile consistent with both the WNT and
SHH groups. In contrast, MP tumors were most similar to Group
C/D tumors, with the exception of a tumor that resembled both
the WNT and Group C/D signatures. To validate these findings,
we compared data from murine tumors to expression profiles
from a distinct set of human MB samples (Cho et al., 2011).
Utilizing a subclass mapping algorithm (Hoshida et al., 2007),
we generated a similarity metric between MP tumors and the
MB subgroups defined in Cho et al. (2011). As shown in Fig-
ure S5, this analysis revealed a high degree of similarity between
MP tumors and the ‘c1’ subtype of human MB, which is charac-
terized by copy number gains of c-MYC and gene expression
signatures indicative of robust MYC transcriptional activity
(Cho et al., 2011).
Finally, we stained an independent set ofMPandPtch1 tumors
with antibodies that have been found to mark each of the four
human MB subgroups (Northcott et al., 2011). Murine Ptch1
mutant tumors expressed high levels of the SHH-subgroup
marker SFRP1 (Figure 6B) and lacked expression of the WNT-
subgroup marker nuclear CTNNB1 (not shown), the Group C
marker NPR3 (Figure 6C), and the Group D marker KCNA1 (Fig-
ure 6D). In contrast, MP tumors exhibited high levels of NPR3
(Figure 6F) and lacked expression of the other markers (Figures
6E and 6G and data not shown). Together, these data suggested
that MP tumors resemble human Group C (MYC-driven) MB.
Gene Expression Profile of MP Tumors
We compared the gene-expression profiles of MP tumors to
those of freshly isolated cerebellar stem cells and tumors from
Ptch1 mutant mice. Using principal component analysis, an
unsupervised approach designed to group samples based on
their similarity in gene expression, we determined that MP
tumors generated by infection of Prom1+Lin stem cells and
those generated by infection of Prom1+ cells were indistinguish-
able based upon global RNA expression (Figure 7A). Both of
these tumor types were distinct from normal (uninfected)ancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc. 159
Figure 5. Myc Is Required for Continued Growth of MP Tumors
(A) Strategy for generating Tet-regulatable MP tumors.
(B–F) Bioluminescent imaging of animals at 1, 2, and 3 weeks after tumor cell transplantation. (B) Representative images of four animals from each group at each
time point (X’s denote animals that died before they could be imaged). Graphs at right show the mean percent increase in bioluminescence for all animals in the
group (with the 1-week signal for each animal set at 100%). In the top graph, the 1- and 2-week time points represent the average signal intensity for all 14 animals;
the 3-week time point (marked by an asterisk) represents the average for the three animals that remained alive at the time of imaging. (C–E) H&E-stained cerebellar
sections from representative animals in Groups 1 (C), 2 (D), and 3 (E) 3 weeks after transplantation. Arrows in (D) and (E) point to the injection site. Scale bars =
250 mm. (F) Survival curve (Groups 1 and 2, n = 14; Group 3, n = 12).
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chical clustering (Figure 7B) confirmed the similarity between
MP tumors generated from Prom1+Lin and Prom1+ cells, as
well as the differences between these tumors, Ptch1 tumors,
and normal stem cells. Focusing on changes in gene expression
of 3-fold and higher (p-value with FDR correction < 0.0001), we
identified 1228 genes (1465 probe sets) that were differentially
expressed between MP tumors and Ptch1 tumors (Com-
parison A, Table S2), and 812 genes (955 probe sets) differen-
tially expressed between MP tumors and normal stem cells
(Comparison B, Table S3).
To learn about the functional significance of these genes, we
analyzed them using gene set enrichment analysis (GSEA) (Sub-160 Cancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc.ramanian et al., 2005) and NextBio software (Kupershmidt et al.,
2010) (see Figure 7 and Table S4 and Table S5). Several impor-
tant correlations emerged from this analysis. First, we noted that
genes expressed at high levels in MP tumors were similar to
those found to be targets of MYC in other studies (Figure 7C,
Table S4 and Table S5). Another set of differentially expressed
genes, which exhibited decreased expression in MP tumors,
were targets of forkhead transcription factors (e.g., Foxo1) (Fig-
ure 7D). This is notable, because FOXO proteins often inhibit
expression of MYC targets, induce expression of MYC antago-
nists, and suppress MYC-induced transformation (Bouchard
et al., 2004, 2007; Delpuech et al., 2007).We also noted amarked
similarity between genes expressed in MP tumors and those
Figure 6. MP Tumors Resemble Human MYC-Driven MB
(A) Gene expression profiles of Myc/DNp53 tumors from Prom1+/Lin cells (MP-pl2-6) or from Prom1+ cells (MP-p3-7) and Ptch1 mutant (Ptc1-4) tumors were
compared to signatures generated from human MB subtypes WNT (blue), SHH (red), and Group C/D (green). Each murine tumor was assigned a score denoting
its similarity to each subtype of human tumor (for details, see Supplemental Experimental Procedures and Table S1).
(B–G) Ptch1 and MP tumors were stained with antibodies specific for secreted frizzled-related protein 1 (SFRP1, a marker for SHH tumors), natriuretic peptide
receptor C (NPR3, a marker for Group C tumors), or potassium voltage-gated channel, shaker-related subfamily, member 1 (KCNA1, a marker for Group D
tumors). Scale bars = 100 mm.
See also Figure S5 and Table S1.
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stem (iPS) cells, including those induced by Oct4 and Klf4 (i.e.,
in the absence of exogenous Myc) (Figure 7F). These genes
were enriched in MP tumors compared to Ptch1 tumors, consis-
tent with the fact that the former are derived from stem cells and
the latter originate from lineage-restricted neuronal progenitors.
However, they were also enriched in MP tumors compared to
cerebellar stem cells, suggesting that MP tumors have adopted
a more primitive differentiation state than the cells from which
they were derived. In support of this notion, MP tumors showed
decreased expression of genes associatedwith neuronal lineage
commitment and differentiation (Figure 7E). Finally, our analysis
revealed significant enrichment of a PI3K signaling gene set, as
well as a set of genes downregulated by rapamycin in another
cancer cell line (Table S4 and Table S5). Notably, analysis of
human MYC-driven (Group c1) tumors using Connectivity Map
(CMAP), an algorithm that screens a given gene expression
signature against a compendium of drug-induced gene expres-
sion signatures (Lamb et al., 2006), suggested that genes regu-
lated by PI3K and mTOR inhibitors are also enriched in these
tumors (Table S6). These observations, and the fact that MP
tumors have decreased expression of Foxo targets, which are
negatively regulated by the PI3K pathway, suggested that this
pathway might play an important role in tumor growth.
MP Tumors Are Sensitive to Inhibitors of PI3 Kinase
and mTOR
To determine whether MP tumors were dependent on PI3K/
mTOR signaling, we first tested the effects of PI3K/mTOR inhib-
itors on tumor cell growth in vitro (Figure 8A). MP tumors showed
complete growth inhibition in the presence of 1–5 mM BEZ-235
(an antagonist of both PI3K and mTOR) and 5 mM BKM-120
(an antagonist of PI3K), and partial inhibition in the presence of
lower concentrations of these compounds. The mTOR antago-Cnist RAD-001 also inhibited growth, albeit incompletely, at
concentrations of 0.2–5 mM. Consistent with their continued
dependency on Myc, tumor cells were dramatically inhibited by
10058-F4, a small molecule that interferes with Myc-Max dimer-
ization (Huang et al., 2006). In contrast, we found that MP tumor
cells showed no growth inhibition in response to the SHH antag-
onist cyclopamine.
To determine whether BEZ-235 and BKM-120 could also
affect long-term tumor cell growth, we cultured MP tumor cells
for 3, 7, or 14 days in the presence of these inhibitors, and
counted cell number at each time point. We found that all three
doses of BEZ-235 inhibited cell growth, whereas only the highest
concentration of BKM-120 (5 mM) was able to cause growth
inhibition (Figure 7B). Similar results were observed when we
used neurosphere assays to measure tumor cell clonogenicity
(Figure S6).
To confirm that these compounds were acting on the PI3K/
mTOR pathway, we performed western blotting to analyze
phosphorylation of critical proteins in the pathway. As shown
in Figure 8C, MP tumor cells showed substantial amounts of
phospho-AKT and phospho-S6 in the absence of inhibitors
(DMSO lanes). Treatment with BEZ-235 or BKM-120 inhibited
phosphorylation of both AKT and S6. In contrast, RAD-001 in-
hibited S6 phosphorylation but did not affect phospho-AKT.
The fact that BEZ-235 and BKM-120 weremore potent inhibitors
of tumor cell proliferation than RAD-001 (Figures 8A and 8B) sug-
gested that blocking activity of PI3K, or both PI3K and mTOR,
might be required for effective tumor inhibition.
To determine whether inhibition of PI3K/mTOR signaling could
also inhibit growth of MP tumors in vivo, we isolated MP tumor
cells and transplanted them into naive NSG mice. After 7 days,
we began treating animals with BKM-120 once daily until clinical
signs of tumor formation were observed. Animals treated with
BKM-120 survived significantly longer than controls (medianancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc. 161
Figure 7. MP Tumors Are Molecularly Distinct from Stem Cells and from Ptch1 Tumors
(A) Principal component analysis (PCA). Three PCA coordinates describe 55.2% of the total data variation (PC1, 27.2%; PC2, 19.8%; and PC3, 8.23%). Green,
MP tumors derived from Prom1+Lin cells; purple, MP tumors derived from Prom1+ cells; blue, Ptch1 tumors; red, normal stem cells (NSCs).
(B) Unsupervised hierarchical clustering analysis. Each column represents a distinct sample and each row represents an individual gene. The normalized (log2)
and standardized (each sample to mean signal = 0 and standard deviation = 1) level of gene expression is denoted by color (green, low; dark, intermediate; red,
high), as indicated in the gradient at the bottom.
(C–F) Genes differentially expressed between MP tumors and Ptch1 tumors (Comp A) were subjected to NextBio analysis, to identify biogroups and studies
(biosets) that contain similar genes. Representative biogroups (C–E) and studies (F) are shown. Venn diagrams show the number of common and unique genes in
both sets. Bars at right show the significance of overlap between gene subsets (the scale of the bar is measured in –log(p-value), so the taller the bar, the higher
the significance of the gene overlap). Whereas each biogroup is represented by a single list of genes, signature genes from studies have two lists, one for
upregulated and one for downregulated genes. Thus, biogroup comparisons consist of just two graphs, whereas comparisons of studies consist of four graphs.
See also Tables S2–S6.
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Modeling MYC-Driven Medulloblastomasurvival = 35 versus 25 days) (Figure 8D). These results suggest
that inhibitors of PI3K/mTOR signaling might be useful for treat-
ment of MYC-driven MB.
DISCUSSION
MYC-drivenMB is a highly malignant pediatric brain tumor that is
often resistant to conventional radiation and chemotherapy.
More effective approaches to treat this disease are critical, and162 Cancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc.these can be facilitated by the development of robust animal
models. The fact that a subset of human MBs exhibit amplifica-
tion or overexpression of MYC prompted us to develop a mouse
model that can be used to investigate the biology of, and test
therapies for, MYC-driven MB.
Cooperation between Myc and Mutant p53
Our observation thatMyc induces proliferation of cerebellar stem
cells is consistent with previous reports showing mitogenic
Figure 8. Growth of MP Tumor Cells Is Inhibited by Antagonists of PI3K/mTOR Signaling
(A) Effects of inhibitors on short-termproliferation. MP tumor cells were cultured in serum-freemedia containing no additive (ø), vehicle (DMSO), cyclopamine (0.1,
1, and 2.5 mM), 10058-F4 (10, 25, and 100 mM), BEZ-235 (0.2, 1, and 5 mM), BKM-120 (0.2, 1, and 5 mM), or RAD-001 (0.2, 1, and 5 mM). For each inhibitor, columns
are ordered from lowest to highest concentration. After 48 hr, cells were pulsed with 3H-Td and cultured overnight before being assayed for 3H-Td incorporation.
Data represent means of triplicate samples ± SEM.
(B) Effects on long-term growth. Tumor cells were cultured for 3, 7, or 14 days in the presence of different doses of inhibitors, and cell number was counted at the
indicated time points.
(C) Effects on PI3K signaling. Tumor cells were treated with DMSO, BEZ-235 (5 mM and 1 mM), BKM-120 (5 mM and 1 mM), RAD-001(5 mM and 1 mM) or cy-
clopamine (2.5 mM and 1 mM) for 3 hr. Cells were lysed and protein was analyzed for phosphorylation of AKT and S6 (pAKT and pS6) or for GAPDH by western
blotting.
(D) Effects on tumor growth in vivo. Five hundred MP tumor cells were retransplanted into naive NSG mice. After 7 days, mice were imaged for luciferase activity
and separated into two groups randomly. Mice in Group 1 were treated with vehicle (0.5% methyl-cellulose) and those in Group 2 were treated with BKM-120
(30mg/kg/d) by oral gavage until they developed symptoms. BMK-120 treatment significantly prolonged survival compared to vehicle (p = 0.001).
See also Figure S6.
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Modeling MYC-Driven Medulloblastomaeffects of Myc in normal and malignant stem cells (Nagao et al.,
2008; Wang et al., 2008). However, while Myc can promote
proliferation of cerebellar stem cells in vitro, it cannot, on its
own, sustain long-term growth in vivo. Our studies suggest
that this is due to Myc-induced apoptosis, but this raises the
question: why are these cellsmore sensitive to apoptosis in vivo?
One reasonmay be that in vitro they aremaintained under condi-
tions that favor neurosphere formation, including high levels of
EGF and bFGF. In the presence of such growth factors, the
proliferative response toMyc often dominates over the apoptotic
response (Harrington et al., 1994). It is also possible that the
in vivo microenvironment contains factors that actively inhibit
growth or survival of transplanted stem cells. In either case, it
is clear that the potent mitogenic effects of Myc are insufficient
to drive transformation.CWhereas stem cells expressingMyc alone do not form tumors,
cells expressing Myc and mutant p53 are highly tumorigenic.
Dysregulation of the TP53 pathway, as evidenced by elevated
expression of p53 protein, is a common feature of human LCA
MB (Eberhart et al., 2005; Frank et al., 2004; Tabori et al.,
2010). Moreover, human MYC-driven MBs often exhibit isochro-
mosome 17q, which is associated with monoallelic loss of
TP53 (Cho et al., 2011; Northcott et al., 2010). Thus, loss of
p53 function could synergize withMYCoverexpression in human
MB as well. The ability of mutant TP53 to cooperate with MYC
has been observed in many other cancers (Elson et al., 1995;
Hemann et al., 2005), but the mechanisms underlying this coop-
eration are not fully understood. In our system, Myc-induced
apoptosis is dependent on endogenous p53, and DNp53 acts,
at least in part, by blocking this function. (Hermeking and Eick,ancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc. 163
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Modeling MYC-Driven Medulloblastoma1994). However, loss of p53 function has also been reported to
increase neural stem cell self-renewal and to promote pluripo-
tency (Kawamura et al., 2009; Meletis et al., 2006; Zheng et al.,
2008), both of which could certainly contribute to transformation.
Moreover, loss of p53 function promotes genomic instability (Ha-
nel and Moll, 2012), which could result in additional mutations
that promote tumor formation. Which of these functions of p53
are most critical in our tumors is the subject of ongoing studies.
Our observation that stem cells can be transformed by the
combination of Myc and DNp53, but not by either gene alone,
suggests that these genes are both required for tumor initiation.
But whether initiating oncogenes continue to be required once
tumors are formed is unclear. Previous studies have demon-
strated that in many types of cancer, tumors become addicted
to expression of the oncogene and undergo regression when
expression is shut off (Jain et al., 2002; Soucek et al., 2008).
However, there have been reports of tumors that continue to
grow even whenMyc is silenced (Boxer et al., 2004). Our results
suggest that continued expression ofMyc is required for mainte-
nance of MP tumor growth. If similar findings hold true for human
MYC-drivenMB, it would suggest that targetingMYC itself might
be an effective approach to therapy.
MP Tumors as a Model for Human MB
The tumors that are induced by Myc and DNp53 resemble
human LCA andMYC-drivenMB. Interestingly, two other groups
have recently described animal models of LCA MB. Deletion of
Rb and p53 in neural progenitors results in tumors that exhibit
amplification of MycN and resemble LCA MB (Shakhova et al.,
2006). Likewise, mice in which MycN is overexpressed in Glt1+
progenitors develop either classic or LCA MB (Swartling et al.,
2010). While each of these tumors exhibits large cell-anaplastic
histology, it is important to note that they may not all represent
the same subtype of MB. We have previously reported that
LCA histology can occur in all molecular subgroups of MB,
including WNT, SHH, Group C and Group D tumors (Northcott
et al., 2010). However, MBs that overexpress MYCN are largely
distinct from those that overexpress MYC. Thus, the models
described by these groups may correspond to human MYCN-
associated MB, whereas MP tumors may represent human
MYC-driven (Group C) MB. Interestingly, tumors from a recently
developed MBmodel in which Rb and p53were deleted in post-
natal cerebellar stem cells did not overexpress MycN and, like
our tumors, expressed high levels of NSC markers (Sutter
et al., 2010). It will be interesting to compare these models at
a molecular level to determine the similarities and differences
between them.
Cellular Origins of Myc-Associated Tumors
Previous studies have shown that activation of the SHH pathway
in GNPs results in MB with 100% penetrance (Schu¨ller et al.,
2008; Yang et al., 2008). Moreover, activation of the SHH
pathway in stem cells within the cerebellar ventricular zone
(VZ) results in expansion of the VZ, but cells do not become
transformed until they commit to the granule lineage (Schu¨ller
et al., 2008; Yang et al., 2008). These studies suggest that
lineage restriction is a critical determinant of susceptibility to
transformation by SHH signaling. The current studies suggest
that Myc + DNp53 can also cause transformation of both stem164 Cancer Cell 21, 155–167, February 14, 2012 ª2012 Elsevier Inc.cells and GNPs. However, once transformed, the stem cells do
not appear to undergo lineage commitment; indeed, their gene
expression profile suggests that Myc/DNp53-transformed cells
are even more immature or undifferentiated than normal neural
stem cells. Moreover, when GNPs are infected with Myc and
DNp53 viruses, they lose expression of GNP lineage markers
during the course of transformation. These results demonstrate
that stem cells and GNPs can both serve as cells of origin
for MYC-driven MB, and suggest that lineage commitment is
not required for (and in fact, may be incompatible with)
transformation.
Molecular Phenotype of MP Tumors
In addition to highlighting the similarities between MP tumors
and human MYC-driven MB, our gene expression analysis also
revealed that genes overexpressed in MP tumors are similar to
those expressed by embryonic and pluripotent stem cells. The
association between pluripotency and cancer has been noted
in a number of other systems. For example, in breast cancer,
glioblastoma and bladder carcinoma, an ES-like signature is
associated with aggressive, poorly differentiated tumors and is
a predictor of poor prognosis (Ben-Porath et al., 2008). Likewise,
a pluripotency signature is associated with transformation of
follicular lymphoma to diffuse large B cell lymphoma (Gentles
et al., 2009). There has been some debate about whether this
signature reflects true acquisition of pluripotent characteristics
or simply activation of a MYC-driven gene expression profile
(Kim et al., 2010). In the case of MP tumors, there is no question
that a Myc-driven transcriptional program is active and plays
a significant role in driving tumor growth. However, it is worth
noting that the genes identified as differentially expressed in
MP tumors also resemble those associated with pluripotency
induced by Oct4 and Klf4, suggesting that the pluripotency
program in our cells is not purely a consequence ofMyc overex-
pression. It is also notable that MP tumors express lower levels
of neural differentiation markers compared to not only Ptch1
tumors (which consist of neuronal progenitor-like cells) but
also normal neural stem cells, from which they were derived.
These findings suggest that transformation of NSCs may involve
dedifferentiation to a more pluripotent state.
Among the most important results of our analysis was the
observation that MP tumors have increased expression of genes
associated with PI3K/AKT/mTOR signaling and decreased
expression of Foxo target genes. FOXO proteins have been
shown to inhibit expression of MYC targets (Bouchard et al.,
2004), and MYC-induced transformation requires inactivation
of FOXO proteins (Bouchard et al., 2007). Importantly, AKT has
been shown to phosphorylate FOXO proteins and thereby
prevent them from entering the nucleus (Bouchard et al.,
2004). Although the cause of PI3K pathway activation in MP
tumors is unclear, it seems likely that this activation interferes
with Foxo activity and thereby synergizes with Myc overexpres-
sion to promote transformation. PI3K signaling has also been
shown to increase Myc protein stability (Kumar et al., 2006)
and to enhance Myc function by promoting degradation of its
antagonist Mad1 (Zhu et al., 2008). Thus, the PI3K pathway
may be a critical regulator of transformation in MP tumors.
In light of the above findings, we hypothesized that inhibition of
PI3K signaling might block growth of MP tumors. Whereas
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Modeling MYC-Driven Medulloblastomainhibition of the SHH pathway had little effect on growth of these
cells, treatment with the PI3K/mTOR inhibitors BEZ-235 and
BKM-120 had a potent inhibitory effect on tumor growth both in-
vitro and in vivo. Several studies have documented activation of
PI3K signaling in human MB (Castellino et al., 2010; Hartmann
et al., 2006). In particular, genomic analysis suggests that
MYC-driven MBs frequently exhibit loss of chromosome 10q
(where PTEN is located) (Northcott et al., 2011). Consistent
with this, our CMAP analysis (Table S6) suggests that MYC-
driven tumors have elevated expression of genes that are regu-
lated by PI3K and mTOR inhibitors. Together, these findings
suggest that targeting the PI3K/mTOR pathway may be useful
for treatment of human MB. Further studies using this model of
MYC-driven MB will shed light on the biology of this disease
and open up new targets for therapy.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6J mice used as a source of stem cells and immunocompromised
(NOD-scid IL2Rgammanull or NSG) mice used for transplantation were
purchased from Jackson Labs (Bar Harbor, ME). Mice were maintained in
the Cancer Center Isolation Facility at Duke University and in the Animal
Facility at Sanford-Burnham. All experiments were performed in accordance
with national guidelines and regulations, and with the approval of the animal
care and use committees at each institution.
Orthotopic Transplantation and Tumor Formation
Before transplantation, cerebellar stem cells (Prom1+Lin cells) or GNPs
(GFP+ cells FACS-sorted from Math1-GFP transgenic mice) were infected
withMyc and DNp53 retroviruses for 20 hr. Either 13 105 stem cells in Neuro-
cult medium or 13 106 GNPs suspended in Neurobasal mediumwere injected
into the cerebella of NSG mice (6–8 weeks old) using a stereotaxic frame with
a mouse adaptor (David Kopf Instruments), as described previously (Yang
et al., 2008). Animals were monitored weekly, and sacrificed when they
showed symptoms of MB.
To generate tetracycline (Tet)-regulatable tumors, stem cells were infected
with Tet-inducible Myc lentivirus and DNp53 retrovirus. The Tet-inducible
vector (pICUE-mycT58A) consisted of a Tet-response element (TRE2) control-
ling expression of turbo red fluorescent protein (tRFP) and Myc-T58A and
a constitutive promoter controlling expression of the reverse tetracycline
transactivator (rtTA3) and eGFP (Meerbrey et al., 2011). Infected cells were im-
planted into cerebella of NSG mice, and mice were maintained on DOX-con-
taining food. When mice became symptomatic, they were sacrificed and
tumor cells were retransplanted into secondary NSG mice. These mice were
separated into three groups. Group 1 (n = 14) was continually fed DOX-con-
taining food, Group 2 (n = 14) was fed DOX-food for one week and normal
food thereafter; and Group 3 (n = 12) was not fed DOX-food at all. Mice
were subjected to bioluminescent imaging at 1, 2, and 3weeks andwere sacri-
ficed at the onset of symptoms. At the time of sacrifice, brains were removed,
paraffin-embedded, sectioned, and stained with H&E.
In Vivo Bioluminescent Imaging
Mice were given intraperitoneal injections of 150 ng/g D-Luciferin (Caliper Life
Sciences, cat#12279) and anesthetized with 2.5% isoflurane. At 7–8 min after
injection, animals were imaged using the Xenogen Spectrum (IVIS-200)
imaging system.
In Vivo Inhibitor Treatment
To study effects of the PI3-kinase antagonist BKM-120 on tumor growth
in vivo, we retransplanted 500 MP tumor cells into the cerebella of secondary
NSG mice. Seven days after transplantation, mice were randomly separated
into two groups: Group 1 was given vehicle (0.5%methyl-cellulose) and Group
2 was given 30 mg/kg BKM-120 by oral gavage once daily until symptom
onset. BKM-120 was dissolved in 0.5% methylcellulose and sonicated usingCan ultrasonicator (Misonix) at an amplitude of 20 for 12 min. Survival was
defined as the time from transplantation until symptom onset.
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